The Randomized Controlled Trial Evaluating Utility of Catheter Ablation Us ing New Strategy Targeting Arrhythmogenic Substrate in Atrial Fibrillation Patients

COmparing New strategy Targeting aRrhythmogenic substrate Of Lasting-A trial Fibrillation Study - CONTROL-AF

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1052210010

Enrollment

Registered

2021-04-22

Start date

2021-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation Atrial fibrillation

Interventions

Patients received CARTO FINDER-guided ablation or ExTRa mapping-guided ablation. In FINDER group, atrial sites of focal activation pattern were ablated, and electrical cardiversion was performed when

D017115

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: First time ablation procedure for persistent atrial fibrillation Patients who can be followed for at least 1-year after procedure Patients from who we get written informed consent

Exclusion criteria

Exclusion criteria: Patients whose atrial fibrillation was restored after only pulmonay veins isolation Patients who received ablation procedure or MAZ E procedure for for atrial fibrillation before enrollment

Design outcomes

Primary

Measure	Time frame
Atrial arrhythmia recurrence beyond 90 days after catheter ablation for atrial fibrillation	—

Secondary

Measure	Time frame
Atrial fibrillation termination rate Atrial fibrillation-free survival, atrial tachycardia-free survival Procedure detail (procedure time, ablation number, ablation region) Adverse events Atrial arrhythmia recurrence beyond 90 days after repeat procedures The difference of results compared between the different ExTRa-guide ablatio n in combined data with ROTATE study Study results compared with matched historical control	—

Measure

Time frame

Atrial fibrillation termination rate Atrial fibrillation-free survival, atrial tachycardia-free survival Procedure detail (procedure time, ablation number, ablation region) Adverse events Atrial arrhythmia recurrence beyond 90 days after repeat procedures The difference of results compared between the different ExTRa-guide ablatio n in combined data with ROTATE study Study results compared with matched historical control

—

Contacts

Public ContactTetsuma Kawaji

Kyoto University Graduate School of Medicine

kawaji@kuhp.kyoto-u.ac.jp+81-75-751-4255

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026